




Orchid Chemicals & Pharmaceuticals Limited					
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2012					
Rs. lakhs					
S. No.	Particulars	Standalone			
		Unaudited			Audited
		Three months ended 30-Jun-12	Three months ended 31-Mar-12	Three months ended 30-Jun-11	Year ended 31-Mar-12
1	Income from Operations				
	a) Net Sales / Income from Operations (Net of Excise Duty)	31563.15	45191.75	37376.02	170170.80
	b) Other Operating Income	4159.90	3886.51	982.87	6293.47
	c) Total income from operations (Net)	35723.05	49078.26	38358.89	176464.27
2	Expenses				
	a) Cost of materials consumed	10193.28	18573.79	21978.82	80241.50
	b) Purchases of stock-in-trade	1538.32	1054.91	1435.55	4546.38
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	7204.14	1124.96	(4846.40)	(6201.86)
	d) Employee benefit expense	3761.80	4004.85	3866.78	15464.59
	e) Depreciation / Amortisation	3991.26	4041.37	3530.47	14905.56
	f) Other Expenses	7444.46	15369.14	7226.60	41242.32
	g) Total Expenses	34133.26	44169.02	33191.82	150198.49
3	Profit/(Loss) from operations before other income, finance costs, exceptional items (1-2)	1589.79	4909.24	5167.06	26265.78
4	Other Income	-	0.29	-	1.59
5	Profit/(Loss) from ordinary activities before finance costs and exceptional items (3+4)	1589.79	4909.53	5167.06	26267.37
6	Finance costs	7132.59	5878.55	3074.74	17905.29
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)	(5542.80)	(969.02)	2092.32	8362.08
8	Exceptional items - Gain / (Loss)	(808.04)	(228.73)	(107.26)	(8388.14)
9	Profit/(Loss) from ordinary activities before Tax (7+8)	(6350.84)	(1197.75)	1985.06	(26.06)
10	Tax expenses				
	- Current Tax & Deferred Tax	(1270.66)	(3252.87)	430.82	(2337.22)
11	Net Profit/(Loss) from ordinary activities after Tax (9-10)	(5080.18)	2055.12	1554.24	2311.16
12	Extraordinary item (net of tax expenses Rs.nil)	-	-	-	8000.00
13	Net Profit/(Loss) for the period (11+12)	(5080.18)	2055.12	1554.24	10311.16
14	Paid-up Equity Share Capital (Face value of Rs.10/- each)	7045.21	7044.21	7044.21	7044.21
15	Reserves excluding Revaluation Reserves	-	-	-	112410.89
16	Earnings per share (EPS) before extra-ordinary items of Rs.10/- each				
	- Basic Rs.	(7.21)*	2.92*	2.21*	3.28
	- Diluted Rs.	(7.21)*	2.92*	1.82*	3.24
17	Earnings per share (EPS) after extra-ordinary items of Rs.10/- each				
	- Basic Rs.	(7.21)*	2.92*	2.21*	14.64
	- Diluted Rs.	(7.21)*	2.92*	1.82*	14.46
<b>A</b>	<b>PARTICULARS OF SHAREHOLDING</b>				
1	Public Shareholding				
	- Number of equity shares	47611295	47601295	48939460	47601295
	- Percentage of Shareholding	67.58	67.57	69.47	67.57
2	Promoters and Promoter group shareholding				
	a. Pledged / Encumbered				
	- Number of shares	17110383	17060383	15745383	17060383
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	74.91	74.69	73.23	74.69
	- Percentage of shares (as a % of the total share capital of the company)	24.29	24.22	22.35	24.22
	b. Non - Encumbered				
	- Number of shares	5730398	5780398	5757233	5780398
	- Percentage of shares (as a % of the total shareholding of the promoter and promoter group)	25.09	25.31	26.77	25.31
	- Percentage of shares (as a % of the total share capital of the company)	8.13	8.21	8.18	8.21
<b>B</b>	<b>INVESTOR COMPLAINTS</b>		3 Months ended 30-Jun-2012		
	Pending at the beginning of the quarter		- NIL -		
	Received during the quarter		3		
	Disposed of during the quarter		3		





* EPS for the period (not annualised)					
1	The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 14, 2012 and have been subjected to limited review by the Statutory Auditors in terms of Clause 41 of the Listing Agreement.				
2	The Company is operating in single segment (i.e) "Pharmaceuticals".				
3	During the quarter, the Company formed a new subsidiary namely Orchid Pharma Singapore Private Limited in Singapore.				
4	<b>Consolidated Results of the company</b>	<b>Three months ended 30-Jun-12</b>	<b>Three months ended 31-Mar-12</b>	<b>Three months ended 30-Jun-11</b>	<b>Year ended 31-Mar-12</b>
	Total Operating Income	40670.74	49019.14	44923.21	190199.09
	EBIDTA (Before Exceptional Item)	5410.90	8867.21	9068.79	41280.65
	Profit After Tax	(5402.51)	1522.67	1692.25	9747.84
5	Exceptional items for the quarter ended June 30, 2012 represents exchange loss on FCQBs / FCTLs of Rs. 808.04 lakhs (Corresponding quarter - Loss of Rs. 107.26 lakhs). The Company had exercised the option provided under the Amendment to the Companies (Accounting Standards) Amendments Rules, 2006 dated March 31, 2009. The Ministry of Corporate Affairs vide notification dated 29th December 2011 has extended the amortisation of gains or losses arising on reporting of Foreign Currency Monetary items over the balance period of such long term asset / liability. Accordingly Exchange Loss on long term foreign currency loans have been amortised over the balance period of such loans. The amount remaining to be amortized in the financial statements as at June 30, 2012 on account of exercising the above option is Rs.11321.20 lakhs (Corresponding quarter - Rs.Nil).				
6	The Allotment Committee of the Board has allotted 10,000 shares to an employee at an adjusted price of Rs.166.15 under Orchid - ESOP 2010 Scheme on May 17, 2012.				
7	Previous period figures have been regrouped wherever necessary.				
				For and on behalf of the Board	
				 <b>K.Raghavendra Rao</b> <b>Chairman &amp; Managing Director</b>	
	Place : Chennai				
	Date : August 14, 2012				

**SNB ASSOCIATES**

CHARTERED ACCOUNTANTS

12, 3rd Floor, Gemini Parsn Complex, 121 Mount Road, Chennai - 600 006.

**AUDITORS' REPORT****TO THE BOARD OF DIRECTORS OF  
ORCHID CHEMICALS AND PHARMACEUTICALS LIMITED****ON LIMITED REVIEW OF UNAUDITED FINANCIAL RESULTS  
FOR THE PERIOD ENDED JUNE 30, 2012**

We have reviewed the accompanying statement of unaudited financial results of **ORCHID CHEMICALS AND PHARMACEUTICALS LIMITED** ("the Company") for the period ended 30th June 2012 except for the disclosures regarding "Public Shareholding" and "Promoter and Promoter Group Shareholding", which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is disclosed, or that it contains any material misstatements except for the figures of consolidated results of the company which were not reviewed by us.

**For SNB ASSOCIATES**  
Chartered Accountants  
Firm Registration No. 015682N

Date: 14<sup>th</sup> August 2012  
Place: Chennai



*B. Mahalingam*  
B. Mahalingam  
Partner  
Membership No. 210408